Scientists find new way to detect abnormal stem cells
27 February, 2006 by Ruth BeranMelbourne scientists have identified a new method of detecting abnormal embryonic stem (ES) cells before they change into cancerous cells.
Replikun contracts UK company to make GMP cell line
21 February, 2006 by Ruth BeranUnlisted immunotherapy company Replikun Biotech has contracted UK-based Cobra Biomanufacturing to build a cell line to manufacture their vaccine and immunotherapy products under GMP conditions.
$6.5m in grants to bird flu projects
20 February, 2006 by Staff WritersThe Commonwealth government has outlined AUD$6.5 million in urgent funding for 33 research projects aiming to prevent, detect or control avian influenza and other respiratory disease outbreaks.
CSL plots its future course with R&D
20 February, 2006 by Graeme O'NeillTo no one's surprise, CSL has become the dominant force in the Australian biotechnology sector. Graeme O'Neill learns from CSL's chief scientist, Andrew Cuthbertson, about the solid research that will drive the company in the next few years.
Dairy CRC develops new stem cell techniques
15 February, 2006 by Ruth BeranScientists at the Dairy Cooperative Research Centre (CRC) have discovered new methods to isolate and maintain large numbers of bovine embryonic stem cells.
Garvan spin-off in $137m anti-inflammatory deal
08 February, 2006 by Helen SchullerG2 Therapies, a spin-off company from Sydney's Garvan Institute of Medical Research, has signed a licensing agreement worth up to AUD$137 million with Denmark's Novo Nordisk to develop, manufacture and commercialise new anti-inflammatory therapies based on G2's C5a receptor antibodies.
Mesoblast implants two with adult stem cells
06 February, 2006 by Ruth BeranThe first two patients in Melbourne-based Mesoblast's (ASX:MSB) clinical trials have been implanted with adult stem cells.
Stem Cell Sciences in new Scottish pact
01 February, 2006 by Ruth BeranStem Cell Sciences (AIM:STEM, SCS) has signed a new tech transfer agreement with the University of Edinburgh, building on a formal collaboration begun in 1994.
CyGenics to open cord blood bank in India
23 January, 2006 by Ruth BeranSingapore-based, ASX-listed cell therapy company CyGenics (ASX:CYN) is the majority shareholder in a new Indian cord blood banking company, to be called CordLife Sciences (India), after an initial investment of AUD$850,000.
Sydney team patents new ES cell growth method
23 January, 2006 by Graeme O'NeillA research team at Sydney's Prince of Wales Hospital has developed and patented a technique for growing human embryonic stem (ES) cells without using animal-derived feeder cells.
US vaccine firm plans ASX listing
20 January, 2006 by Helen SchullerUS-based private vaccine development company Vaccinoma is planning to raise AUD$15 million through an IPO on the ASX in early April.
Pera to leave Stem Cell Centre for California
17 January, 2006 by Ruth BeranInternationally renowned embryonic stem cell expert Martin Pera will leave Monash University and the Australian Stem Cell Centre (ASCC) in April to head the newly created Institute for Stem Cell and Regenerative Medicine (ISCRM) at the University of Southern California.
Mesoblast granted stem cell patent
17 January, 2006 by Helen SchullerMelbourne based adult stem cell company, Mesoblast (ASX:MSB), has been granted what it says is a key adult stem cell patent.
Researchers pay tribute to stem cell review chair
16 January, 2006 by Staff WritersThe research community has paid tribute to Justice John Lockhart, the chair of a recently concluded review of Australia's stem cell legislation, who died in Sydney on Friday after a brief illness.
The Lockhart review: what people think
20 December, 2005 by Ruth BeranThe recommendations from the independent stem cell legislation review committee chaired by former Federal Court judge John Lockhart have been welcomed by many of Australia's stem cell research scientists as well as biotechnology and patient advocacy groups.
